182 related articles for article (PubMed ID: 11036024)
1. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori.
Tsutsui N; Taneike I; Ohara T; Goshi S; Kojio S; Iwakura N; Matsumaru H; Wakisaka-Saito N; Zhang HM; Yamamoto T
Antimicrob Agents Chemother; 2000 Nov; 44(11):3069-73. PubMed ID: 11036024
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
Ohara T; Goshi S; Taneike I; Tamura Y; Zhang HM; Yamamoto T
Helicobacter; 2001 Jun; 6(2):125-9. PubMed ID: 11422467
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.
Kawakami Y; Akahane T; Yamaguchi M; Oana K; Takahashi Y; Okimura Y; Okabe T; Gotoh A; Katsuyama T
Antimicrob Agents Chemother; 2000 Feb; 44(2):458-61. PubMed ID: 10639386
[TBL] [Abstract][Full Text] [Related]
4. Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils.
Suzuki H; Miyazawa M; Nagahashi S; Sato M; Bessho M; Nagata H; Miura S; Ishii H
J Gastroenterol Hepatol; 2003 Jul; 18(7):787-95. PubMed ID: 12795750
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.
Tsuchiya M; Imamura L; Park JB; Kobashi K
Biol Pharm Bull; 1995 Aug; 18(8):1053-6. PubMed ID: 8535394
[TBL] [Abstract][Full Text] [Related]
6. [In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
Taneike I; Tamura Y; Shimizu T; Yamashiro Y; Toyoda S; Yamamoto T
Kansenshogaku Zasshi; 2000 Jul; 74(7):601-2. PubMed ID: 10965666
[No Abstract] [Full Text] [Related]
7. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Sharara AI
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
[TBL] [Abstract][Full Text] [Related]
8. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
9. Review article: the pharmacology of rabeprazole.
Williams MP; Pounder RE
Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():3-10. PubMed ID: 10491723
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
Iwahi T; Satoh H; Nakao M; Iwasaki T; Yamazaki T; Kubo K; Tamura T; Imada A
Antimicrob Agents Chemother; 1991 Mar; 35(3):490-6. PubMed ID: 2039199
[TBL] [Abstract][Full Text] [Related]
11. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
[TBL] [Abstract][Full Text] [Related]
12. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
13. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Miwa H; Ohkura R; Murai T; Sato K; Nagahara A; Hirai S; Watanabe S; Sato N
Aliment Pharmacol Ther; 1999 Jun; 13(6):741-6. PubMed ID: 10383502
[TBL] [Abstract][Full Text] [Related]
14. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori.
Hirai M; Azuma T; Ito S; Kato T; Kohli Y
J Gastroenterol; 1995 Aug; 30(4):461-4. PubMed ID: 7550855
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth.
Nakajima N; Kuwayama H; Iwasaki A; Arakawa Y
J Clin Gastroenterol; 1995; 20 Suppl 2():S90-2. PubMed ID: 7594352
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
Vogt K; Hahn H
Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
[TBL] [Abstract][Full Text] [Related]
17. Bacteriostatic and bactericidal activity of rabeprazole against Helicobacter pylori.
Garza-González E; Tijerina-Menchaca R; Pérez-Pérez GI; Bosques-Padilla FJ
J Chemother; 2004 Dec; 16(6):612-3. PubMed ID: 15700857
[No Abstract] [Full Text] [Related]
18. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lansoprazole in eradication of Helicobacter pylori.
Takimoto T; Ido K; Taniguchi Y; Satoh K; Saifuku K; Kihira K; Yoshida Y; Kimura K
J Clin Gastroenterol; 1995; 20 Suppl 2():S121-4. PubMed ID: 7594327
[TBL] [Abstract][Full Text] [Related]
20. Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Barth J; Hahne W
Aliment Pharmacol Ther; 2002 Mar; 16 Suppl 1():31-3. PubMed ID: 11849125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
